Suryaram Gummuluru, PhD
Professor
Boston University Chobanian & Avedisian School of Medicine
Virology, Immunology & Microbiology

PhD, University of Rochester
MS, University of Rochester
BSc, University Saskatchewan



Our research is broadly focused on the role of dendritic cells (DCs) in the initiation and propagation of HIV-1 replication. Since dendritic cells are believed to be the first immune competent cells to encounter virus in the genital mucosa, a thorough understanding of the HIV-DC interactions is of paramount importance. DCs can capture virus particles independently of CD4 and co-receptor complexes, and retain them in an infectious state for an extended period of time. These virus-bearing DCs may then facilitate a more efficient spread of virus to replication-permissive CD4+ T cells. Our recent work has identified a novel glycosphingolipid dependent mechanism of virus attachment to DCs. The fate of the virus particle post-attachment in DCs remains unclear. Virion trafficking within the DC bypasses conventional endocytic organelles, i.e., endosomes and lysosomes. Virus localization within this novel vesicular compartment not only has the potential to protect the invading HIV from being degraded, but also creates a latent reservoir of virus, which could present a major challenge for eradication by antiretroviral therapy. Furthermore, the mechanism of subsequent return of infectious virus particles to the cell surface and the method of subsequent transmission to T cells remains unclear. Current studies utilizing biochemical and microscopic approaches are underway to monitor HIV-1 trafficking and localization in the DC and its subsequent transfer to T cells.

Faculty
Boston University
National Emerging Infectious Disease Lab


Member
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




Providence/Boston Center for AIDS Research (CFAR): Core Support (Cores A, B, G, K, L, SWG)
07/01/2023 - 06/30/2028 (Co-Investigator of Sub-Project / SP)
The Miriam Hospital NIH NIAID
2P30AI042853-25

Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis
03/17/2023 - 02/28/2027 (Multi-PI)
PI: Suryaram Gummuluru, PhD
NIH/National Institute of Allergy & Infectious Diseases
1R01AI175068-01A1

Persistent HIV-1 expression and microglia dysfunction
08/01/2021 - 05/31/2026 (Multi-PI)
PI: Suryaram Gummuluru, PhD
Boston Medical Center Corporation NIH NIDA
5R01DA055488-03

Single Cell Transcriptomics of the Opioid Use Disorder ad HIV Syndemic in the Human Brain
11/05/2020 - 08/31/2025 (Multi-PI)
PI: Suryaram Gummuluru, PhD
J. Craig Venter Institute NIH NIDA
5UM1DA051411-03

Research Training in Immunology
08/24/2020 - 07/31/2025 (PI)
NIH/National Institute of Allergy & Infectious Diseases
5T32AI007309-34

Plasmonic Inactivation of Virus and Mycoplasma Contaminants
08/01/2021 - 05/31/2025 (Multi-PI)
PI: Suryaram Gummuluru, PhD
NIH/National Institute of General Medical Sciences
5R01GM142012-03

Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by opiates and HIV Infection
07/15/2020 - 04/30/2025 (Multi-PI)
PI: Suryaram Gummuluru, PhD
NIH/National Institute on Drug Abuse
5R01DA051889-04

Dual antiretroviral loaded nanoparticles for long-acting suppressive HIV therapy
02/28/2023 - 02/27/2025 (Key Person / Mentor)
NIH/National Institute of Allergy & Infectious Diseases
1F31AI172625-01

Persistent HIV expression induced type 1 IFN responses and inflammaging
08/01/2018 - 04/30/2024 (PI)
NIH/National Institute on Aging
5R01AG060890-05

GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues
11/08/2017 - 10/31/2023 (Multi-PI)
PI: Suryaram Gummuluru, PhD
NIH/National Institute of Allergy & Infectious Diseases
5R01AI132111-05

Showing 10 of 20 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2024 Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis 5R01AI175068-02
2024 Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection 5R01DA051889-05
2023 Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis 1R01AI175068-01A1
2023 Plasmonic Inactivation of Virus and Mycoplasma Contaminants 5R01GM142012-03
2023 Persistent HIV-1 expression and microglia dysfunction 5R01DA055488-03
2023 Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection 5R01DA051889-04
2023 Research Training in Immunology 5T32AI007309-34
2022 Persistent HIV-1 expression and microglia dysfunction 5R01DA055488-02
2022 Plasmonic Inactivation of Virus and Mycoplasma Contaminants 5R01GM142012-02
2022 Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection 5R01DA051889-03
Showing 10 of 48 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Nisa A, Kumar R, Ramasamy S, Kolloli A, Olejnik J, Jalloh S, Gummuluru S, Subbian S, Bushkin Y. Modulations of Homeostatic ACE2, CD147, GRP78 Pathways Correlate with Vascular and Endothelial Performance Markers during Pulmonary SARS-CoV-2 Infection. Cells. 2024 Feb 29; 13(5).View Related Profiles. PMID: 38474396; PMCID: PMC10930588; DOI: 10.3390/cells13050432;
     
  2. Komori M, Morey AL, Quiñones-Molina AA, Fofana J, Romero L, Peters E, Matsuda K, Gummuluru S, Smith JF, Akahata W, Akiyama H. Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine. bioRxiv. 2023 Nov 01.View Related Profiles. PMID: 37961509; PMCID: PMC10634970; DOI: 10.1101/2023.11.01.565056;
     
  3. de Oliveira Junior GP, Welsh JA, Pinckney B, Palu CC, Lu S, Zimmerman A, Barbosa RH, Sahu P, Noshin M, Gummuluru S, Tigges J, Jones JC, Ivanov AR, Ghiran IC. Human red blood cells release microvesicles with distinct sizes and protein composition that alter neutrophil phagocytosis. J Extracell Biol. 2023 Nov; 2(11). PMID: 37942280; PMCID: PMC10629908; DOI: 10.1002/jex2.107;
     
  4. Tseng AE, Carossino M, Gertje HP, O'Connell AK, Gummuluru S, Kolachalama VB, Balasuriya UBR, Connor JH, Bennett RS, Liu DX, Hensley LE, Crossland NA. Hepatic proinflammatory myeloid phenotypes are a hallmark of Ebola virus Kikwit pathogenesis in rhesus monkeys. Vet Pathol. 2023 Jul; 60(4):473-487.View Related Profiles. PMID: 37170900
     
  5. Zang H, Siddiqui M, Gummuluru S, Wong WW, Reinhard BM. Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T-Cell Activation at the Immunological Synapse. ACS Nano. 2022 Nov 22; 16(11):18408-18420. PMID: 36282488; PMCID: PMC9815837; DOI: 10.1021/acsnano.2c06516;
     
  6. Jalloh S, Olejnik J, Berrigan J, Nisa A, Suder EL, Akiyama H, Lei M, Ramaswamy S, Tyagi S, Bushkin Y, Mühlberger E, Gummuluru S. CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. PLoS Pathog. 2022 Oct; 18(10):e1010479.View Related Profiles. PMID: 36279285; PMCID: PMC9632919; DOI: 10.1371/journal.ppat.1010479;
     
  7. Boytz R, Slabicki M, Ramaswamy S, Patten JJ, Zou C, Meng C, Hurst BL, Wang J, Nowak RP, Yang PL, Sattler M, Stone RM, Griffin JD, Gray NS, Gummuluru S, Davey RA, Weisberg E. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy. J Med Virol. 2023 Jan; 95(1):e28157.View Related Profiles. PMID: 36117402; PMCID: PMC9538324; DOI: 10.1002/jmv.28157;
     
  8. Patten JJ, Keiser PT, Morselli-Gysi D, Menichetti G, Mori H, Donahue CJ, Gan X, Valle ID, Geoghegan-Barek K, Anantpadma M, Boytz R, Berrigan JL, Stubbs SH, Ayazika T, O'Leary C, Jalloh S, Wagner F, Ayehunie S, Elledge SJ, Anderson D, Loscalzo J, Zitnik M, Gummuluru S, Namchuk MN, Barabási AL, Davey RA. Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization. iScience. 2022 Sep 16; 25(9):104925.View Related Profiles. PMID: 35992305; PMCID: PMC9374494; DOI: 10.1016/j.isci.2022.104925;
     
  9. Jalloh S, Olejnik J, Berrigan J, Nisa A, Suder EL, Akiyama H, Lei M, Tyagi S, Bushkin Y, Mühlberger E, Gummuluru S. CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. bioRxiv. 2022 Mar 30.View Related Profiles. PMID: 35378756; PMCID: PMC8978933; DOI: 10.1101/2022.03.29.486190;
     
  10. Zang H, Fofana J, Xu F, Nodder SB, Gummuluru S, Reinhard BM. Characterizing Lipid-Coated Mesoporous Silica Nanoparticles as CD169-Binding Delivery System for Rilpivirine and Cabotegravir. Adv Nanobiomed Res. 2022 May; 2(5). PMID: 36313942; PMCID: PMC9610980; DOI: 10.1002/anbr.202100157;
     
Showing 10 of 65 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 65 publications over 27 distinct years, with a maximum of 7 publications in 2022

YearPublications
19941
19952
19962
19971
19981
19991
20001
20022
20031
20061
20071
20081
20091
20101
20124
20132
20145
20153
20163
20176
20183
20193
20205
20213
20227
20233
20241
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

dendritic cells
glycosphingolipids
HIV pathogenesis
Virological synapse
virus attachment, trafficking, and cell-mediated virus transfer

Available to Mentor as: (Review Mentor Role Definitions):
  • Research / Scholarly Mentor
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Gummuluru's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department